These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system. Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262 [TBL] [Abstract][Full Text] [Related]
4. Expression of glutamate transporter, GABRA6, serine proteinase inhibitor 2 and low levels of glutamate and GABA in the brain of knock-out mouse for Canavan disease. Surendran S; Rady PL; Michals-Matalon K; Quast MJ; Rassin DK; Campbell GA; Ezell EL; Wei J; Tyring SK; Szucs S; Matalon R Brain Res Bull; 2003 Aug; 61(4):427-35. PubMed ID: 12909286 [TBL] [Abstract][Full Text] [Related]
5. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease. Eke GH; Iscan A; Cece H; Calik M Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636 [TBL] [Abstract][Full Text] [Related]
6. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease. Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900 [TBL] [Abstract][Full Text] [Related]
7. Molecular basis of Canavan's disease: from human to mouse. Surendran S; Matalon KM; Tyring SK; Matalon R J Child Neurol; 2003 Sep; 18(9):604-10. PubMed ID: 14572138 [TBL] [Abstract][Full Text] [Related]
8. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy. von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375 [TBL] [Abstract][Full Text] [Related]
9. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time. Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242 [TBL] [Abstract][Full Text] [Related]
10. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model. Becker I; Wang-Eckhardt L; Eckhardt M J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891 [TBL] [Abstract][Full Text] [Related]
11. Canavan disease: clinical features and recent advances in research. Hoshino H; Kubota M Pediatr Int; 2014 Aug; 56(4):477-83. PubMed ID: 24977939 [TBL] [Abstract][Full Text] [Related]
12. Mental retardation and hypotonia seen in the knock out mouse for Canavan disease is not due to succinate semialdehyde dehydrogenase deficiency. Surendran S; Ezell EL; Quast MJ; Wei J; Tyring SK; Michals-Matalon K; Matalon R Neurosci Lett; 2004 Mar; 358(1):29-32. PubMed ID: 15016427 [TBL] [Abstract][Full Text] [Related]
13. Mouse neural progenitor cells differentiate into oligodendrocytes in the brain of a knockout mouse model of Canavan disease. Surendran S; Shihabuddin LS; Clarke J; Taksir TV; Stewart GR; Parsons G; Yang W; Tyring SK; Michals-Matalon K; Matalon R Brain Res Dev Brain Res; 2004 Oct; 153(1):19-27. PubMed ID: 15464214 [TBL] [Abstract][Full Text] [Related]
14. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease. Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013 [TBL] [Abstract][Full Text] [Related]
15. Nur7 is a nonsense mutation in the mouse aspartoacylase gene that causes spongy degeneration of the CNS. Traka M; Wollmann RL; Cerda SR; Dugas J; Barres BA; Popko B J Neurosci; 2008 Nov; 28(45):11537-49. PubMed ID: 18987190 [TBL] [Abstract][Full Text] [Related]
16. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Janson C; McPhee S; Bilaniuk L; Haselgrove J; Testaiuti M; Freese A; Wang DJ; Shera D; Hurh P; Rupin J; Saslow E; Goldfarb O; Goldberg M; Larijani G; Sharrar W; Liouterman L; Camp A; Kolodny E; Samulski J; Leone P Hum Gene Ther; 2002 Jul; 13(11):1391-412. PubMed ID: 12162821 [TBL] [Abstract][Full Text] [Related]
17. New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion. Di Pietro V; Cavallari U; Amorini AM; Lazzarino G; Longo S; Poggiani C; Cavalli P; Tavazzi B Clin Biochem; 2013 Dec; 46(18):1902-4. PubMed ID: 24036223 [TBL] [Abstract][Full Text] [Related]
18. Aspartoacylase gene knockout results in severe vacuolation in the white matter and gray matter of the spinal cord in the mouse. Surendran S; Campbell GA; Tyring SK; Matalon R Neurobiol Dis; 2005 Mar; 18(2):385-9. PubMed ID: 15686967 [TBL] [Abstract][Full Text] [Related]
19. Spongy degeneration of the brain, Canavan disease: biochemical and molecular findings. Matalon RM; Michals-Matalon K Front Biosci; 2000 Mar; 5():D307-11. PubMed ID: 10704428 [TBL] [Abstract][Full Text] [Related]
20. Aspartoacylase gene knockout in the mouse: impact on reproduction. Surendran S; Szucs S; Tyring SK; Matalon R Reprod Toxicol; 2005; 20(2):281-3. PubMed ID: 15907664 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]